These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23977937)

  • 1. Prophylaxis and therapy of plague.
    Oyston PC; Williamson ED
    Expert Rev Anti Infect Ther; 2013 Aug; 11(8):817-29. PubMed ID: 23977937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Live-attenuated Yersinia pestis vaccines.
    Wang X; Zhang X; Zhou D; Yang R
    Expert Rev Vaccines; 2013 Jun; 12(6):677-86. PubMed ID: 23750796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plague.
    Williamson ED
    Vaccine; 2009 Nov; 27 Suppl 4():D56-60. PubMed ID: 19837288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague.
    Powell BS; Andrews GP; Enama JT; Jendrek S; Bolt C; Worsham P; Pullen JK; Ribot W; Hines H; Smith L; Heath DG; Adamovicz JJ
    Biotechnol Prog; 2005; 21(5):1490-510. PubMed ID: 16209555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CONTEMPORARY TENDENCIES IN CONSTRUCTING RECOMBINANT VACCINES FOR SPECIFIC PROPHYLAXIS OF PLAGUE].
    Mikshis NI; Kudryavtseva OM; Kutyrev VV
    Zh Mikrobiol Epidemiol Immunobiol; 2015; (3):116-26. PubMed ID: 26259281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for new plague vaccines.
    Feodorova VA; Corbel MJ
    Expert Rev Vaccines; 2009 Dec; 8(12):1721-38. PubMed ID: 19943765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic Therapy of Plague: A Review.
    Sebbane F; Lemaître N
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34065940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yersinia pestis: still a plague in the 21st century.
    Josko D
    Clin Lab Sci; 2004; 17(1):25-9. PubMed ID: 15011977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Protective activity of the recombinant strain Salmonella minnesota R595/GSA, synthesizing the plague capsule antigen in experimental plague in mice].
    Gremiakova TA; Stepanshina VN; Korobova OV; Anisimov GA
    Mol Gen Mikrobiol Virusol; 1994; (1):23-6. PubMed ID: 8133846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plague Vaccines: Status and Future.
    Sun W
    Adv Exp Med Biol; 2016; 918():313-360. PubMed ID: 27722869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potency of killed plague vaccines prepared from avirulent Yersinia pestis.
    Williams JE; Altieri PL; Berman S; Lowenthal JP; Cavanaugh DC
    Bull World Health Organ; 1980; 58(5):753-6. PubMed ID: 6975184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective efficacy of a recombinant plague vaccine when co-administered with another sub-unit or live attenuated vaccine.
    Griffin K; Bedford R; Townson K; Phillpotts R; Funnell S; Morton M; Williamson D; Titball R
    FEMS Immunol Med Microbiol; 2005 Mar; 43(3):425-30. PubMed ID: 15708318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Early protection of animals, immunized by a recombinant plague vaccine, from experimental plague].
    Gremiakova TA; Amel'chenko VA; Anisimov GA
    Biull Eksp Biol Med; 1995 Jan; 119(1):54-7. PubMed ID: 7718805
    [No Abstract]   [Full Text] [Related]  

  • 14. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salmonella-based plague vaccines for bioterrorism.
    Calhoun LN; Kwon YM
    J Microbiol Immunol Infect; 2006 Apr; 39(2):92-7. PubMed ID: 16604240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-plague vaccination: past and future perspectives].
    Merlin M
    Bull Soc Pathol Exot; 1999 Dec; 92(5 Pt 2):427-31. PubMed ID: 11000956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How the structural gene products of Yersinia pestis relate to virulence.
    Brubaker RR
    Future Microbiol; 2007 Aug; 2(4):377-85. PubMed ID: 17683274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plague history: Yersin's discovery of the causative bacterium in 1894 enabled, in the subsequent century, scientific progress in understanding the disease and the development of treatments and vaccines.
    Butler T
    Clin Microbiol Infect; 2014 Mar; 20(3):202-9. PubMed ID: 24438235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs.
    Feodorova VA; Pan'kina LN; Savostina EP; Sayapina LV; Motin VL; Dentovskaya SV; Shaikhutdinova RZ; Ivanov SA; Lindner B; Kondakova AN; Bystrova OV; Kocharova NA; Senchenkova SN; Holst O; Pier GB; Knirel YA; Anisimov AP
    Vaccine; 2007 Nov; 25(44):7620-8. PubMed ID: 17913308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Yersinia pestis YscN ATPase mutant functions as a live attenuated vaccine against bubonic plague in mice.
    Bozue J; Cote CK; Webster W; Bassett A; Tobery S; Little S; Swietnicki W
    FEMS Microbiol Lett; 2012 Jul; 332(2):113-21. PubMed ID: 22537022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.